Der US-Auftrag an BAVARIAN NORDIC ist mehr als 1 Billion DKK wert !!! - 500 Beiträge pro Seite

[smallpox]

Hier ein Ausschnitt aus der Reuters-Meldung:

» ..... Under the contract Bavarian must develop a plan for large scale manufacture of the vaccine to demonstrate how the company could deliver up to 30 million doses to the federal government.

"Production and delivery of the 30 million doses is an order worth more than a billion crowns," Bavarian chairman of the board Asger Aamund told Reuters.

He expects Bavarian will receive the actual order for delivery of the 30 million doses within the next six months. And after that, the U.S. government is expected to order another 250-300 million doses, Aamund said. .....«

Es lohnt sich noch, einzusteigen. Wer weiß, wie das aussieht, wenn die Amierikaner auf die Meldung reagieren

..... und kaufen

[MrFel]

Billion auf Englisch=Milliarde auf Deutsch

[smallpox]

..... na klar!
Und wer den Umtauschkurs nicht kennt: 1Euro = 7,4126 DKK

1 Bio DKK sind da immer noch ca. 135 Mio Euro !!!

[stockbaby]

Neu bei bn. - bitte beachtet den 6. absatz!

Announcement No. 05-03
26 February 2003


Bavarian Nordic initiates Phase II of the clinical development of MVA-BN as a safe smallpox vaccine

Open as PDF in Danish Open as PDF in English

As stated in Bavarian Nordic’s announcement of yesterday, US Secretary of Health Tommy G. Thompson has awarded Bavarian Nordic A/S a three-year contract to develop the company’s proprietary MVA-BN safe smallpox vaccine for the US government.


Whilst the US contract supports early development, Bavarian Nordic is now entering into a Phase II clinical study.

The study will further evaluate the safety and immunogenicity of MVA-BN in 165 healthy volunteers. The study will be conducted in Switzerland and enrolment will commence during March 2003.

This announcement follows the completion of Bavarian Nordic’s Phase I clinical trial that is the only study evaluating safe smallpox vaccines to be completed worldwide. The Phase I clinical trial evaluated the safety of various doses of MVA-BN in a total of 86 healthy volunteers and has generated extremely encouraging results demonstrating the great potential of MVA-BN as a safe smallpox vaccine. The highest dose of MVA-BN was well tolerated with no reports of any serious adverse events.

Importantly, at this dose MVA-BN was also shown to induce high levels of immunity (antibody and cellular immune response) in 100% of individuals who had previously not been vaccinated against smallpox. Moreover, MVA-BN was also well tolerated and significantly boosted the immune responses (antibody and cellular immune response) in people that had previously been vaccinated against smallpox many years before.

Bavarian Nordic is now the only company to have already completed small animal studies and a clinical Phase I trial, demonstrating the excellent safety and immunogenicity of MVA-BN and the superiority over other MVA strains. In addition, Bavarian Nordic is the only company who has already produced and supplied commercial quantities of MVA.

Peter Wulff, President and CEO of Bavarian Nordic: “Bavarian Nordic is now taking a huge step in the clinical development and licensure of MVA-BN by entering clinical Phase II studies. This achievement makes us the leading company developing a safe smallpox vaccine”.

Further information regarding the data from Phase I and the plans for Phase II trials will be presented by Mr. Peter Wulff, President & CEO of Bavarian Nordic, at the BIO-CEO conference in New York, today 26 February 2003 at 15.00 hours EST.

Copenhagen, 26 February 2003
Asger Aamund, Chairman of the Board

[smallpox]

Yeesss !

[stockbaby]

na heute schon die bild - zeitung gelesen!
die amis kaufen 30 mio impfdosen bei bn.
außerdem wird über den die mva technologie im einsatz bei aids berichtet. 1. testphase war ja sehr erfolgreich!
langsam dürften sich die aufträge auch auf den kurs niederschlagen. gobt ja auch noch anleger in usa!